Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of 18F-2-fluoro-2-deoxy-D-glucose Produced by a New Manufacturer, for Safety, Through the Identification of Adverse Events, and Efficacy, Through the Evaluation of Its Ability, When Utilized in Performance of a Positron Emission Tomography Computed Tomography Scan, to Correctly Distinguish Benign From Malignant Solitary Pulmonary Nodules.

NCT04615156 is registered in ClinicalTrials.gov with Eastern Health, Canada as lead sponsor.

NCT NCT04615156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04615156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of 18F-2-fluoro-2-deoxy-D-glucose Produced by a New Manufacturer, for Safety, Through the Identification of Adverse Events, and Efficacy, Through the Evaluation of Its Ability, When Utilized in Performance of a Positron Emission Tomography Computed Tomography Scan, to Correctly Distinguish Benign From Malignant Solitary Pulmonary Nodules.
Lead sponsor
Eastern Health, Canada
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 1, 2020
Completion date
November 1, 2027
Enrollment
10,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

18f-2-fluoro-2-deoxy-d-glucose, adverse event, oncology, solitary pulmonary nodule